#BEGIN_DRUGCARD DB02574

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C51H79N11O22

# Chemical_IUPAC_Name:
2-amino-3-({[3-(4-{3-[(3-nitro-5-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)formamido]propyl}piperazin-1-yl)propyl]carbamoyl}oxy)propyl N-[3-(4-{3-[(3-nitro-5-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)formamido]propyl}piperazin-1-yl)propyl]carbamate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
BV2

# HET_ID:
BV2

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C51H79N11O22/c52-33(29-79-50(73)55-7-3-11-59-17-13-57(14-18-59)9-1-5-53-46(71)31-21-34(61(75)76)25-36(23-31)81-48-44(69)42(67)40(65)38(27-63)83-48)30-80-51(74)56-8-4-12-60-19-15-58(16-20-60)10-2-6-54-47(72)32-22-35(62(77)78)26-37(24-32)82-49-45(70)43(68)41(66)39(28-64)84-49/h21-26,33,38-45,48-49,63-70H,1-20,27-30,52H2,(H,53,71)(H,54,72)(H,55,73)(H,56,74)/t38-,39-,40-,41-,42+,43+,44-,45-,48-,49-/m1/s1

# InChI_Key:
InChIKey=RJLCAAJYVGPDFG-SUFADMTCSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2574

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
1198.2335

# Molecular_Weight_Mono:
1197.540113267

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1RD9

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.03

# Predicted_LogS:
-3.2

# Predicted_Water_Solubility:
6.91e-01 g/l

# Primary_Accession_No:
DB02574

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936429

# PubChem_Substance_ID:
46508919

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00780

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC(COC(=O)NCCCN1CCN(CCCNC(=O)C2=CC(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)=CC(=C2)[N+]([O-])=O)CC1)COC(=O)NCCCN1CCN(CCCNC(=O)C2=CC(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)=CC(=C2)[N+]([O-])=O)CC1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:16 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X00171

# Drug_Target_1_GenBank_ID_Protein:
48348

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
ctxB

# Drug_Target_1_Gene_Sequence:
>375 bp
ATGATTAAATTAAAATTTGGTGTTTTTTTTACAGTTTTACTATCTTCAGCATATGCACAT
GGAACACCTCAAAATATTACTGATTTGTGTGCAGAATCACACAACACACAAATATATACG
CTAAATGATAAGATATTTTCGTATACAGAATCTCTAGCTGGAAAAAGAGAGATGGCTATC
ATTACTTTTAAGAATGGTGCAATTTTTCAAGTAGAAGTACCAAGTAGTCAACATATAGAT
TCACAAAAAAAAGCGATTGAAAGGATGAAGGATACCCTGAGGATTGCATATCTTACTGAA
GCTAAAGTCGAAAAGTTATGTGTATGGAATAATAAAACGCCTCATGCGATTGCCGCAATT
AGTATGGCAAATTAA

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
10952301	Heidelberg JF, Eisen JA, Nelson WC, Clayton RA, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Umayam L, Gill SR, Nelson KE, Read TD, Tettelin H, Richardson D, Ermolaeva MD, Vamathevan J, Bass S, Qin H, Dragoi I, Sellers P, McDonald L, Utterback T, Fleishmann RD, Nierman WC, White O, Salzberg SL, Smith HO, Colwell RR, Mekalanos JJ, Venter JC, Fraser CM: DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae. Nature. 2000 Aug 3;406(6795):477-83.
11447291	Aman AT, Fraser S, Merritt EA, Rodigherio C, Kenny M, Ahn M, Hol WG, Williams NA, Lencer WI, Hirst TR: A mutant cholera toxin B subunit that binds GM1- ganglioside but lacks immunomodulatory or toxic activity. Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8536-41. Epub 2001 Jul 10.
11880036	Pickens JC, Merritt EA, Ahn M, Verlinde CL, Hol WG, Fan E: Anchor-based design of improved cholera toxin and E. coli heat-labile enterotoxin receptor binding antagonists that display multiple binding modes. Chem Biol. 2002 Feb;9(2):215-24.
12405825	Zhang Z, Merritt EA, Ahn M, Roach C, Hou Z, Verlinde CL, Hol WG, Fan E: Solution and crystallographic studies of branched multivalent ligands that inhibit the receptor-binding of cholera toxin. J Am Chem Soc. 2002 Nov 6;124(44):12991-8.
13679513	Fujinaga Y, Wolf AA, Rodighiero C, Wheeler H, Tsai B, Allen L, Jobling MG, Rapoport T, Holmes RK, Lencer WI: Gangliosides that associate with lipid rafts mediate transport of cholera and related toxins from the plasma membrane to endoplasmic reticulm. Mol Biol Cell. 2003 Dec;14(12):4783-93. Epub 2003 Sep 17.
3214	Gill DM: The arrangement of subunits in cholera toxin. Biochemistry. 1976 Mar 23;15(6):1242-8.
6315707	Lockman H, Kaper JB: Nucleotide sequence analysis of the A2 and B subunits of Vibrio cholerae enterotoxin. J Biol Chem. 1983 Nov 25;258(22):13722-6.
6646234	Mekalanos JJ, Swartz DJ, Pearson GD, Harford N, Groyne F, de Wilde M: Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development. Nature. 1983 Dec 8-14;306(5943):551-7.
7658472	Zhang RG, Westbrook ML, Westbrook EM, Scott DL, Otwinowski Z, Maulik PR, Reed RA, Shipley GG: The 2.4 A crystal structure of cholera toxin B subunit pentamer: choleragenoid. J Mol Biol. 1995 Aug 25;251(4):550-62.
8003954	Merritt EA, Sarfaty S, van den Akker F, L'Hoir C, Martial JA, Hol WG: Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. Protein Sci. 1994 Feb;3(2):166-75.
8181723	Lebens M, Holmgren J: Structure and arrangement of the cholera toxin genes in Vibrio cholerae O139. FEMS Microbiol Lett. 1994 Apr 1;117(2):197-202.
903362	Lai CY: Determination of the primary structure of cholera toxin B subunit. J Biol Chem. 1977 Oct 25;252(20):7249-56.
903363	Kurosky A, Markel DE, Peterson JW: Covalent structure of the beta chain of cholera enterotoxin. J Biol Chem. 1977 Oct 25;252(20):7257-64.
9232653	Merritt EA, Sarfaty S, Jobling MG, Chang T, Holmes RK, Hirst TR, Hol WG: Structural studies of receptor binding by cholera toxin mutants. Protein Sci. 1997 Jul;6(7):1516-28.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2723

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
13957

# Drug_Target_1_Name:
Cholera enterotoxin subunit B

# Drug_Target_1_Number_of_Residues:
124

# Drug_Target_1_PDB_ID:
1S5F

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01376	Enterotoxin_b

# Drug_Target_1_Protein_Sequence:
>Cholera enterotoxin subunit B precursor
MIKLKFGVFFTVLLSSAYAHGTPQNITDLCAEYHNTQIYTLNDKIFSYTESLAGKREMAI
ITFKNGAIFQVEVPGSQHIDSQKKAIERMKDTLRIAYLTEAKVEKLCVWNNKTPHAIAAI
SMAN

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-21

# Drug_Target_1_Specific_Function:
The B subunit pentameric ring directs the A subunit to its target by binding to the GM1 gangliosides present on the surface of the intestinal epithelial cells. It can bind five GM1 gangliosides. It has no toxic activity by itself

# Drug_Target_1_SwissProt_ID:
P01556

# Drug_Target_1_SwissProt_Name:
CHTB_VIBCH

# Drug_Target_1_Synonyms:
Cholera enterotoxin B chain
Cholera enterotoxin gamma chain
Cholera enterotoxin subunit B precursor
Choleragenoid

# Drug_Target_1_Theoretical_pI:
9.09

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB02574
